Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 4 | 5 |
| List of Tables | 6 | 2 |
| List of Figures | 8 | 1 |
| Critical Care Market to 2017 Introduction | 9 | 1 |
| GBI Research Report Guidance | 9 | 1 |
| Critical Care Market to 2017 Global Overview | 10 | 2 |
| Critical Care Market to 2017 Geographical Landscape | 12 | 5 |
| Introduction | 12 | 1 |
| The US | 13 | 1 |
| Revenue | 13 | 1 |
| Top Five Countries of Europe | 14 | 1 |
| Revenue | 14 | 2 |
| Japan | 16 | 1 |
| Revenue | 16 | 1 |
| Critical Care Market to 2017 Therapeutic Landscape | 17 | 53 |
| Factor XIII Concentrate | 17 | 1 |
| Introduction | 17 | 1 |
| Revenue | 18 | 3 |
| Geographical Segmentation | 21 | 1 |
| Cost of Treatment | 22 | 2 |
| Treatment Usage Pattern | 24 | 1 |
| Diseased Population | 25 | 1 |
| Diagnosed Population | 25 | 1 |
| Drivers and Restraints | 25 | 1 |
| Drivers | 26 | 1 |
| Anticipated Launch of rFXIII will Drive the Market in Future | 26 | 1 |
| Better Safety and Efficacy as Compared to Other Human Derived Blood Products | 26 | 1 |
| Restraint | 26 | 1 |
| Lack of Robust Data on the Use of Factor XIII Concentrates in High Risk Surgical Settings | 26 | 1 |
| Marketed Products | 27 | 1 |
| Fibrogammin P / Corifact | 27 | 1 |
| Product Description | 27 | 1 |
| Mechanism of Action | 27 | 1 |
| Antithrombin (AT) Market | 27 | 1 |
| Introduction | 27 | 2 |
| Revenue | 29 | 2 |
| Geographical Segmentation | 31 | 1 |
| Cost of Treatment | 32 | 1 |
| Treatment Usage Pattern | 33 | 1 |
| Diseased Population | 34 | 1 |
| Diagnosed Population | 34 | 1 |
| Patients on AT Concentrates | 35 | 1 |
| Drivers and Restraints | 35 | 1 |
| Drivers | 36 | 1 |
| Better Safety and Efficacy of AT Concentrate will Increase the Uptake in the Forecast Period | 36 | 1 |
| Launch of Atryn will Drive the AT Concentrate Market | 36 | 1 |
| Restraints | 36 | 1 |
| Lack of Robust Scientific Evidence about Usefulness of AT Concentrates | 36 | 1 |
| Comparatively High Cost of Therapy with AT Concentrates | 36 | 1 |
| Marketed Products | 37 | 1 |
| Thrombate III (Antithrombin III human) | 37 | 1 |
| Product Description | 37 | 1 |
| Mechanism of Action | 37 | 1 |
| Anbinex (Grifols SA) | 37 | 1 |
| Kybernin (CSL Behring GmbH) | 38 | 1 |
| Aclotine (Laboratory of French Split and Biotechnology) | 38 | 1 |
| ANTITHROMBIN III (Baxter) | 38 | 1 |
| Neuart (Mitsubishi Tanabe Pharma Corporation) | 39 | 1 |
| Atryn | 39 | 1 |
| Product Description | 39 | 1 |
| Mechanism of Action | 39 | 1 |
| Fibrinogen Concentrate Market | 40 | 1 |
| Introduction | 40 | 1 |
| Revenue | 41 | 1 |
| Geographical Segmentation | 42 | 3 |
| Cost of Treatment | 45 | 1 |
| Treatment Usage Pattern | 46 | 1 |
| Diseased Population | 46 | 1 |
| Diagnosed Population | 46 | 1 |
| Patients on Fibrinogen Concentrate | 46 | 2 |
| Drivers and Restraints | 48 | 1 |
| Drivers | 48 | 1 |
| Increasing Uptake of Fibrinogen Concentrates | 48 | 1 |
| Barriers | 48 | 1 |
| Lack of Robust Data on Use of Factor Concentrates | 48 | 1 |
| Marketed Products | 49 | 1 |
| Haemocomplettan/Riastap | 49 | 1 |
| Product Description | 49 | 1 |
| Mechanism of Action | 49 | 1 |
| Albumin | 50 | 1 |
| Introduction | 50 | 1 |
| Revenue | 51 | 2 |
| Geographical Segmentation | 53 | 1 |
| Cost of Treatment | 54 | 2 |
| Treatment Usage Pattern | 56 | 1 |
| Drivers and Restraints | 57 | 1 |
| Drivers | 57 | 1 |
| Increasing Cost and Therapeutic Uses of Albumin will Drive the Growth of the Albumin Market | 57 | 1 |
| Restraints | 57 | 1 |
| Lack of Clinical Data for Use of Human Albumin in Various Clinical Settings will Restrict Growth of the Albumin Market | 57 | 1 |
| Relatively High Price of Human Albumin May Act as a Barrier for the Global Albumin Market in Upcoming Years | 58 | 1 |
| Marketed Products | 58 | 1 |
| Albuminar (CSL Behring) | 58 | 1 |
| Human Albumin Biotest, solution for infusion (Biotest) | 58 | 1 |
| Buminate 25% (Baxter) | 59 | 1 |
| Human Albumin Grifols 25% (Grifols SA) | 59 | 1 |
| Prothrombin Complex Concentrate Market (PCC) | 59 | 1 |
| Introduction | 59 | 1 |
| Oral Anticoagulant Reversal | 60 | 1 |
| Other Indications | 60 | 1 |
| Revenue | 61 | 2 |
| Revenue Breakup | 63 | 1 |
| Geographical Segmentation | 64 | 1 |
| Cost of Treatment | 65 | 1 |
| Treatment Usage Pattern | 66 | 1 |
| Drivers and Restraints | 67 | 1 |
| Drivers | 67 | 1 |
| Preference for PCC as Compared to Other Alternatives will Drive the Growth of the PCC Market in the Forecast Period | 67 | 1 |
| Increased use of PCC for Various Bleeding Complications | 68 | 1 |
| Barriers | 68 | 1 |
| Lack of Clinical Data for the use of PCC in Various Possible Indications is Restraining the Growth of the PCC Market | 68 | 1 |
| Marketed Products | 68 | 1 |
| Beriplex P/N | 68 | 1 |
| Product Description | 68 | 1 |
| Mechanism of Action | 68 | 1 |
| Feiba | 69 | 1 |
| Product Description | 69 | 1 |
| Mechanism of Action | 69 | 1 |
| Critical Care Market to 2017 - Product Pipeline | 70 | 3 |
| Introduction | 70 | 2 |
| rFXIII (Novo Nordisk A/S) | 72 | 1 |
| Critical Care Market to 2017 Competitive Landscape | 73 | 7 |
| CSL Limited | 73 | 1 |
| Company Overview | 73 | 1 |
| SWOT Analysis | 74 | 1 |
| Octapharma AG | 74 | 1 |
| Company Overview | 74 | 1 |
| SWOT Analysis | 75 | 1 |
| Baxter International Inc. | 76 | 1 |
| SWOT Analysis | 76 | 1 |
| Grifols SA (Grifols) | 77 | 1 |
| Company Overview | 77 | 1 |
| SWOT Analysis | 78 | 1 |
| LFB S.A. (LFB) | 79 | 1 |
| Company Overview | 79 | 1 |
| SWOT Analysis | 79 | 1 |
| Critical Care Market to 2017 Mergers &Acquisitions Landscape | 80 | 1 |
| LFB Biotechnologies Completes Acquisition of GTC Biotherapeutics | 80 | 1 |
| Grifols Completes Acquisition of Talecris Biotherapeutics | 80 | 1 |
| Critical Care Market to 2017 Appendix | 81 | 7 |
| Market Definitions | 81 | 1 |
| Abbreviations | 81 | 1 |
| Research Methodology | 82 | 2 |
| Coverage | 82 | 1 |
| Secondary Research | 82 | 1 |
| Primary Research | 83 | 1 |
| Therapeutic Landscape | 83 | 3 |
| Epidemiology-based Forecasting | 84 | 2 |
| Geographical Landscape | 86 | 1 |
| Pipeline Analysis | 86 | 1 |
| Competitive Landscape | 86 | 1 |
| Expert Panel Validation | 86 | 1 |
| Contact Us | 86 | 1 |
| Disclaimer | 86 | 1 |
| Sources | 87 | 1 |